AirProductsAndChemicals

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 1 week ago

Helium demand to double by 2035, tracking chip production boom, report says

Helium demand to double by 2035, tracking chip production boom, report says Sept 9 (Reuters) - The global demand for helium is likely to nearly double by 2035, backed mostly by a rise in demand from the semiconductor industry due to the lack of viable alternatives, according to a report by market research firm IDTechEx. Global demand could exceed 322 million cubic meters by 2035 for the gas used widely in manufacturing due to its cooling and inert properties, said the report, released in August.

Reuters - 3 weeks ago

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over

Reuters - 4 weeks ago

Air Products to buy hydrogen production assets in Uzbekistan

Air Products to buy hydrogen production assets in Uzbekistan TASHKENT, Aug 21 (Reuters) - Uzbekistan's Saneg, which owns the Ferghana oil refinery, has agreed to sell its hydrogen production assets to United States' Air Products APD.N for $140 million, the Uzbek company said on Wednesday. "The acquisition includes a steam methane reforming unit, capable of processing either 100% natural gas or LPG for high reliability operations," it said in a statement, adding that the deal is expected to close

Reuters - 4 weeks ago

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises

Reuters - 1 month ago

Nike shares jump as Ackman's return sparks turnaround hopes

UPDATE 1-Nike shares jump as Ackman's return sparks turnaround hopes Updates to add graphic By Ananya Mariam Rajesh Aug 15 (Reuters) - Nike shares NKE.N gained nearly 4% on Thursday as investors hoped the return of billionaire William Ackman as a stakeholder could spark a turnaround at the sportswear giant that has been battling with strategy missteps and tough competition.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.